Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response
| dc.contributor.author | Snyder, Benjamin M. | |
| dc.contributor.author | Lion, Alex H. | |
| dc.contributor.author | Helvie, Amy E. | |
| dc.contributor.author | Marshall, Mark S. | |
| dc.contributor.author | Ferguson, Michael J. | |
| dc.contributor.department | Pediatrics, School of Medicine | |
| dc.date.accessioned | 2023-10-18T12:51:36Z | |
| dc.date.available | 2023-10-18T12:51:36Z | |
| dc.date.issued | 2023-01-03 | |
| dc.description.abstract | Here we present a case of metastatic PNET which arose from an immature teratoma that was refractory to standard Ewing sarcoma chemotherapy. This PNET was determined to have elevated levels of ALK protein via IHC. The patient was treated with crizotinib on a palliative basis with a sustained response. | |
| dc.eprint.version | Final published version | |
| dc.identifier.citation | Snyder BM, Lion AH, Helvie AE, Marshall MS, Ferguson MJ. Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response. Clin Case Rep. 2023;11(1):e6779. Published 2023 Jan 3. doi:10.1002/ccr3.6779 | |
| dc.identifier.uri | https://hdl.handle.net/1805/36432 | |
| dc.language.iso | en_US | |
| dc.publisher | Wiley | |
| dc.relation.isversionof | 10.1002/ccr3.6779 | |
| dc.relation.journal | Clinical Case Reports | |
| dc.rights | Attribution 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.source | PMC | |
| dc.subject | Ewing sarcoma | |
| dc.subject | PNET | |
| dc.subject | Crizotinib | |
| dc.subject | Precision oncology | |
| dc.title | Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response | |
| dc.type | Article |